These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. Prognostic value of left atrial strain in patients with wild-type transthyretin amyloid cardiomyopathy. Oike F; Usuku H; Yamamoto E; Yamada T; Egashira K; Morioka M; Nishi M; Komorita T; Hirakawa K; Tabata N; Yamanaga K; Fujisue K; Hanatani S; Sueta D; Arima Y; Araki S; Takashio S; Oda S; Misumi Y; Kawano H; Matsushita K; Ueda M; Matsui H; Tsujita K ESC Heart Fail; 2021 Dec; 8(6):5316-5326. PubMed ID: 34582129 [TBL] [Abstract][Full Text] [Related]
8. Identification of wild-type transthyretin cardiac amyloidosis in patients with carpal tunnel syndrome surgery (CACTuS). Ladefoged B; Clemmensen T; Dybro A; Hartig-Andreasen C; Kirkeby L; Gormsen LC; Bomholt P; Gillmore J; Poulsen SH ESC Heart Fail; 2023 Feb; 10(1):234-244. PubMed ID: 36193570 [TBL] [Abstract][Full Text] [Related]
9. Reduced trans-mitral A-wave velocity predicts the presence of wild-type transthyretin amyloidosis in elderly patients with left ventricular hypertrophy. Yamamura S; Izumiya Y; Ishida T; Onoue Y; Kimura Y; Hanatani S; Araki S; Fujisue K; Sueta D; Kanazawa H; Takashio S; Usuku H; Sugamura K; Sakamoto K; Yamamoto E; Yamamuro M; Yasuda H; Kojima S; Kaikita K; Hokimoto S; Ogawa H; Tsujita K Heart Vessels; 2017 Jun; 32(6):708-713. PubMed ID: 27882404 [TBL] [Abstract][Full Text] [Related]
10. Wild-type transthyretin amyloidosis as a cause of heart failure with preserved ejection fraction. González-López E; Gallego-Delgado M; Guzzo-Merello G; de Haro-Del Moral FJ; Cobo-Marcos M; Robles C; Bornstein B; Salas C; Lara-Pezzi E; Alonso-Pulpon L; Garcia-Pavia P Eur Heart J; 2015 Oct; 36(38):2585-94. PubMed ID: 26224076 [TBL] [Abstract][Full Text] [Related]
11. Use of Ventilatory Efficiency Slope as a Marker for Increased Mortality in Wild-Type Transthyretin Cardiac Amyloidosis. Yunis A; Doros G; Luptak I; Connors LH; Sam F Am J Cardiol; 2019 Jul; 124(1):122-130. PubMed ID: 31053293 [TBL] [Abstract][Full Text] [Related]
12. Features of atrial fibrillation in wild-type transthyretin cardiac amyloidosis: a systematic review and clinical experience. Mints YY; Doros G; Berk JL; Connors LH; Ruberg FL ESC Heart Fail; 2018 Oct; 5(5):772-779. PubMed ID: 29916559 [TBL] [Abstract][Full Text] [Related]
13. Determining patterns of vascular function and structure in wild-type transthyretin cardiac amyloidosis. A comparative study. Stamatelopoulos K; Delialis D; Georgiopoulos G; Tselegkidi MI; Theodorakakou F; Dialoupi I; Bambatsias D; Petropoulos I; Vergaro G; Ikonomidis I; Tzortzis S; Briasoulis A; Kanakakis J; Trougakos I; Dimopoulos MA; Kastritis E Int J Cardiol; 2022 Sep; 363():102-110. PubMed ID: 35716935 [TBL] [Abstract][Full Text] [Related]
14. Clinical characteristics and natural history of wild-type transthyretin amyloid cardiomyopathy in Japan. Yamada T; Takashio S; Arima Y; Nishi M; Morioka M; Hirakawa K; Hanatani S; Fujisue K; Yamanaga K; Kanazawa H; Sueta D; Araki S; Usuku H; Nakamura T; Suzuki S; Yamamoto E; Ueda M; Kaikita K; Tsujita K ESC Heart Fail; 2020 Oct; 7(5):2829-2837. PubMed ID: 32672425 [TBL] [Abstract][Full Text] [Related]
15. Value of Longitudinal Strain to Identify Wild-Type Transthyretin Amyloidosis in Patients With Aortic Stenosis. Robin G; Cognet T; Bouisset F; Cariou E; Méjean S; Pradel S; Colombat M; Galinier M; Carrié D; Lairez O; Circ J; 2021 Aug; 85(9):1494-1504. PubMed ID: 33980765 [TBL] [Abstract][Full Text] [Related]
16. Early Experience of Tafamidis Treatment in Japanese Patients With Wild-Type Transthyretin Cardiac Amyloidosis From the Kochi Amyloidosis Cohort. Ochi Y; Kubo T; Baba Y; Sugiura K; Miyagawa K; Noguchi T; Hirota T; Hamada T; Yamasaki N; Kitaoka H Circ J; 2022 Jun; 86(7):1121-1128. PubMed ID: 35599003 [TBL] [Abstract][Full Text] [Related]
17. Prevalence of cardiac amyloidosis among elderly patients with systolic heart failure or conduction disorders. López-Sainz Á; de Haro-Del Moral FJ; Dominguez F; Restrepo-Cordoba A; Amor-Salamanca A; Hernandez-Hernandez A; Ruiz-Guerrero L; Krsnik I; Cobo-Marcos M; Castro V; Toquero-Ramos J; Lara-Pezzi E; Fernandez-Lozano I; Alonso-Pulpon L; González-López E; Garcia-Pavia P Amyloid; 2019 Sep; 26(3):156-163. PubMed ID: 31210553 [No Abstract] [Full Text] [Related]
18. Clinical and apparative investigation of large and small nerve fiber impairment in mixed cohort of ATTR-amyloidosis: impact on patient management and new insights in wild-type. Papagianni A; Ihne S; Zeller D; Morbach C; Üçeyler N; Sommer C Amyloid; 2022 Mar; 29(1):14-22. PubMed ID: 34632904 [TBL] [Abstract][Full Text] [Related]
19. Cardiac Amyloidosis: Overlooked, Underappreciated, and Treatable. Rubin J; Maurer MS Annu Rev Med; 2020 Jan; 71():203-219. PubMed ID: 31986086 [TBL] [Abstract][Full Text] [Related]